Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology

Laboratory Investigation

Volumn 83, Issue 3, 2003, Pages 409-417

  Sekijima, Yoshiki ^a,b   Hammarström, Per ^a   Matsumura, Miyuki ^c   Shimizu, Yuko ^c   Iwata, Makoto ^c   Tokuda, Takahiko ^b   Ikeda, Shu ichi ^b   Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PREALBUMIN;

ADULT; AMYLOIDOSIS; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHOROID PLEXUS; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; HUMAN; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN VARIANT; THERMODYNAMICS;

EID: 0037344272     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000059937.11023.1F     Document Type: Article

References (44)

1. Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, Plante V, Ducot B, Ichai P, Lacroix C, Metral S, Bismuth H, and Said G (2000). The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 123:1495-1504.
2. Ando Y, Almeida M, Ohlsson PI, Ando E, Negi A, Suhr O, Terazaki H, Obayashi K, Ando M, and Saraiva MJ (1999). Unusual self-association properties of transthyretin Y114C related to familial amyloidotic polyneuropathy: Effects on detection and quantification. Biochem Biophys Res Commun 261:264-269.
3. Ando Y, Tanaka Y, Nakazato M, Ericzon BG, Yamashita T, Tashima K, Sakashita N, Suga M, Uchino M, and Ando M (1995). Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation. Biochem Biophys Res Commun 211:354-358.
4. Brett M, Persey MR, Reilly MM, Revesz T, Booth DR, Booth SE, Hawkins PN, Pepys MB, and Morgan-Hughes JA (1999). Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain 122:183-190.
5. Colon W and Kelly JW (1992). Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31:8654-8660.
6. Connors LH, Richardson AM, Theberge R, and Costello CE (2000). Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid 7:54-69.
7. Dickson PW, Aldred AR, Menting JG, Marley PD, Sawyer WH, and Schreiber G (1987). Thyroxine transport in choroid plexus. J Biol Chem 262:13907-13915.
8. Ellie E, Camou F, Vital A, Rummens C, Grateau G, Delpech M, and Valleix S (2001). Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). Neurology 57:135-137.
9. Fan JQ, Ishii S, Asano N, and Suzuki Y (1999). Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5:112-115.
10. Garzuly F, Wisniewski T, Brittig F, and Budka H (1996). Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). Neurology 47:1562-1567.
11. Hammarström P, Jiang X, Hurshman AR, Powers ET, and Kelly JW (2002). Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 99:16927-16932.
12. Hammarström P, Schneider F, and Kelly JW (2001). Transsuppression of misfolding in an amyloid disease. Science 293:2459-2462.
13. Herrick MK, DeBruyne K, Horoupian DS, Skare J, Vanefsky MA, and Ong T (1996). Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene. Neurology 47:988-992.
14. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, and Pepys MB (1993). Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341:1113-1116.
15. Horta JDS, Filipe I, and Duarte S (1964). Portuguese polyneuritic familial type amyloidosis. Pathol Microbiol 27:809-825.
16. Ikeda S, Nakazato M, Ando Y, and Sobue G (2002). Familial transthyretin-type amyloid polyneuropathy in Japan: Clinical and genetic heterogeneity. Neurology 58:1001-1007.
17. Jacobson DR, McFarlin DE, Kane I, and Buxbaum JN (1992). Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum Genet 89:353-356.
18. Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, and Buxbaum JN (1996). Revised transthyretin IIe 122 allele frequency in African-Americans. Hum Genet 98:236-238.
19. Jenne DE, Denzel K, Blatzinger P, Winter P, Obermaier B, Linke RP, and Altland K (1996). A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis. Proc Natl Acad Sci USA 93:6302-6307.
20. Jiang X, Buxbaum JN, and Kelly JW (2001a). The V1221 cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA 98:14943-14948.
21. Jiang X, Smith CS, Petrassi HM, Hammarström P, White JT, Sacchettini JC, and Kelly JW (2001 b). An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 40:11442-11452.
22. Kelly JW (1996). The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 6:11-17.
23. Kelly JW (1997). Amyloid fibril formation and protein misassembly: A structural quest for insights into amyloid and prion diseases. Structure 5:595-600.
24. Lai Z, Colon W, and Kelly JW (1996). The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 35:6470-6482.
25. Lashuel HA, Wurth C, Woo L, and Kelly JW (1999). The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions Biochemistry 38:13560-13573.
26. Mascalchi M, Salvi F, Pirini MG, D'Errico A, Ferlini A, Lolli F, Plasmati R, Tessa C, Villari N, and Tassinari CA (1999). Transthyretin amyloidosis and superficial siderosis of the CNS. Neurology 53:1498-1503.
27. McCutchen SL, Colon W, and Kelly JW (1993). Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry 32:12119-12127.
28. McCutchen SL, Lai Z, Miroy GJ, Kelly JW, and Colon W (1995). Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 34:13527-13536.
29. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, and Kelly JW (1996). Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA 93:15051-15056.
30. Nakazato M, Kangawa K, Minamino N, Tawara S, Matsuo H, and Araki S (1984). Radioimmunoassay for detecting abnormal prealbumin in the serum for diagnosis of familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 122:719-725.
31. Petersen RB, Goren H, Cohen M, Richardson SL, Tresser N, Lynn A, Gali M, Estes M, and Gambetti P (1997). Transthyretin amyloidosis: A new mutation associated with dementia. Ann Neurol 41:307-313.
32. Purkey HE, Dorrell MI, and Kelly JW (2001). Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc Natl Acad Sci USA 98:5566-5571.
33. Ranlov I, Alves IL, Ranlov PJ, Husby G, Costa PP, and Saraiva MJ (1992). A Danish kindred with familial amyloid cardiomyopathy revisited: Identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers. Am J Med 93:3-8.
34. Sakashita N, Ando Y, Jinnouchi K, Yoshimatsu M, Terazaki H, Obayashi K, and Takeya M (2001). Familial amyloidotic polyneuropathy (ATTR Val30yMet) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int 51:476-480.
35. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, and Kelly JW (2002). Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 99:15428-15433.
36. Schneider F, Hammarström P, and Kelly JW (2001). Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci 10:1606-1613.
37. Schreiber G, Aldred AR, Jaworowski A, Nilsson C, Achen MG, and Segal MB (1990). Thyroxine transport from blood to brain via transthyretin synthesis in choroid plexus. Am J Physiol 258:R338-R345.
38. Sekijima Y, Tokuda T, Kametani F, Tanaka K, Maruyama K, and Ikeda S (2001). Serum transthyretin monomer in patients with familial amyloid polyneuropathy. Amyloid 8:257-262.
39. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, and Saraiva MJ (2001). Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: Evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159:1993-2000.
40. Tachibana N, Tokuda T, Yoshida K, Taketomi T, Nakazato M, Li YF, Masuda Y, and Ikeda S (1999). Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid 6:282-288.
41. Uemichi T, Liepnieks JJ, and Benson MD (1997). A trinucleotide deletion in the transthyretin gene (delta V 122) in a kindred with familial amyloidotic polyneuropathy. Neurology 48:1667-1670.
42. Uemichi T, Uitti RJ, Koeppen AH, Donat JR, and Benson MD (1999). Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch Neurol 56:1152-1155.
43. Ushiyama M, Ikeda S, and Yanagisawa N (1991). Transthyretintype cerebral amyloid angiopathy in type I familial amyloid polyneuropathy. Acta Neuropathol (Berl) 81:524-528.
44. Yamamoto K, Hsu SP, Yoshida K, Ikeda S, Nakazato M, Shiomi K, Cheng SY, Furihata K, Ueno I, and Yanagisawa N (1994). Familial amyloid polyneuropathy in Taiwan: Identification of transthyretin variant (Leu55Pro). Muscle Nerve 17:637-641.